Health
Personalized mRNA Melanoma Vaccine Plus Keytruda Cut Recurrence or Death Risk 42 Percent in Phase 3 Trial
Detailed INTerpath-001 data from Merck and Moderna show the individualized vaccine lowered recurrence risk in resected melanoma, but only after six months, and overall survival is not yet mature.
Oct 25, 2026
